Literature DB >> 18796623

Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells.

Emanuela Rosati1, Rita Sabatini, Giuliana Rampino, Antonio Tabilio, Mauro Di Ianni, Katia Fettucciari, Andrea Bartoli, Stefano Coaccioli, Isabella Screpanti, Pierfrancesco Marconi.   

Abstract

Notch signaling is involved in tumorigenesis, but its role in B-chronic lymphocytic leukemia (B-CLL) pathogenesis is not completely defined. This study examined the expression and activation of Notch receptors in B-CLL cells and the role of Notch signaling in sustaining the survival of these cells. Our results show that B-CLL cells but not normal B cells constitutively express Notch1 and Notch2 proteins as well as their ligands Jagged1 and Jagged2. Notch signaling is constitutively activated in B-CLL cells, and its activation is further increased in B-CLL cells, which resist spontaneous apoptosis after 24-hour ex vivo culture. Notch stimulation by a soluble Jagged1 ligand increases B-CLL cell survival and is accompanied by increased nuclear factor-kappa B (NF-kappaB) activity and cellular inhibitor of apoptosis protein 2 (c-IAP2) and X-linked inhibitor of apoptosis protein (XIAP) expression. In contrast, Notch-signaling inhibition by the gamma-secretase inhibitor I (GSI; z-Leu-Leu-Nle-CHO) and the specific Notch2 down-regulation by small-interfering RNA accelerate spontaneous B-CLL cell apoptosis. Apoptotic activity of GSI is accompanied by reduction of NF-kappaB activity and c-IAP2 and XIAP expression. Overall, our findings show that Notch signaling plays a critical role in B-CLL cell survival and apoptosis resistance and suggest that it could be a novel potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18796623     DOI: 10.1182/blood-2008-02-139725

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  121 in total

1.  Post-transcriptional silencing of Notch2 mRNA in chronic lymphocytic [corrected] leukemic cells of B-CLL patients.

Authors:  Kaneez Fatima; Rehan Zafar Paracha; Ishtiaq Qadri
Journal:  Mol Biol Rep       Date:  2011-12-10       Impact factor: 2.316

2.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Giulia Fabbri; Valeria Spina; Marco Fangazio; Francesco Forconi; Roberto Marasca; Luca Laurenti; Alessio Bruscaggin; Michaela Cerri; Sara Monti; Stefania Cresta; Rosella Famà; Lorenzo De Paoli; Pietro Bulian; Valter Gattei; Anna Guarini; Silvia Deaglio; Daniela Capello; Raul Rabadan; Laura Pasqualucci; Riccardo Dalla-Favera; Robin Foà; Gianluca Gaidano
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

3.  Activation of the NOTCH1 pathway in chronic lymphocytic leukemia.

Authors:  Valentina Gianfelici
Journal:  Haematologica       Date:  2012-03       Impact factor: 9.941

4.  Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis.

Authors:  Silvia Rasi; Sara Monti; Valeria Spina; Robin Foà; Gianluca Gaidano; Davide Rossi
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

Review 5.  Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

Authors:  Ying Huang; Jia-Zhu Wu; Jian-Yong Li; Wei Xu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

Review 6.  Cutaneous T-cell lymphomas: a review of new discoveries and treatments.

Authors:  Tara Bloom; Timothy M Kuzel; Christiane Querfeld; Joan Guitart; Steven T Rosen
Journal:  Curr Treat Options Oncol       Date:  2012-03

7.  Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia.

Authors:  F Arruga; B Gizdic; S Serra; T Vaisitti; C Ciardullo; M Coscia; L Laurenti; G D'Arena; O Jaksic; G Inghirami; D Rossi; G Gaidano; S Deaglio
Journal:  Leukemia       Date:  2013-10-30       Impact factor: 11.528

8.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Authors:  S Jeromin; S Weissmann; C Haferlach; F Dicker; K Bayer; V Grossmann; T Alpermann; A Roller; A Kohlmann; T Haferlach; W Kern; S Schnittger
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

9.  A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia.

Authors:  P Sportoletti; S Baldoni; B Del Papa; P Aureli; E Dorillo; L Ruggeri; S Plebani; V Amico; A Di Tommaso; E Rosati; P Marconi; M Di Ianni; F Falzetti
Journal:  Leukemia       Date:  2013-10-09       Impact factor: 11.528

10.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.